The iQ3Corp. business model is unique in that it leverages off its relationship with The iQ Group Global companies and other industry participants, and also combines its expertise in corporate finance advisory with scientific expertise in drug development and commercialisation.
This gives iQ3Corp. a clear advantage when it comes to understanding the needs of early stage biotech.
Australia is a global life science hub with over 1000 unlisted private biotech companies.
These companies represent iQ3Corp.’s target market and a great opportunity for iQ3Corp., as they will inevitably require corporate advisory and capital raising services.
iQ3Corp. is currently working as the Lead Manager on FarmaForce’s Initial Public Offering (IPO), raising a minimum of $5,000,000 and a maximum of $6,000,000 for the company’s ASX listing.